Case Report: Hyperandrogenism in Menopause

Title:Case Report: Hyperandrogenism in Menopause

Volume: 24

Author(s): Felicia Visconti*, Francesca Garino, Ginevra Corneli, Marcella Libera Balbo, Cristina Gottero, Daniela Sansone and Salvatore Endrio Oleandri

Affiliation:

• S.C. Endocrinologia e malattie Metaboliche, ASL Città di Torino, Turin, Italy

Abstract: Background: Postmenopausal androgen excess often occurs due to the imbalance between the rapid decline in ovarian estrogen and a relatively gradual decline in androgen secretion. The rapid onset of hirsutism, alopecia, and acne, on the other hand, is a rare occurrence and requires further investigation in order to rule out an underlying neoplasm.

Case Report: A 54-year-old woman arrived at the endocrinology outpatient clinic for the appearance of hirsutism and defluvium capitis in the past 9 months. She had hypertrichosis of the face, trunk, and mammary areolae and reduced timbre of voice. Circulating androgens were higher than normal levels (testosterone: 7.7 ng/mL, DHEAS: 5437 mcg/L, 17-OH-progesterone: 3.1 nmol/L), gonadotropin and prolactin levels were normal, and Nugent test was negative. Abdominal CT scan was negative for adrenal lesions, while transvaginal ovarian ultrasonography revealed a left adnexal formation (19x18x24 mm) compatible with stromal neoplasm. A bilateral hysteroannessiectomy was performed. Histological examination was diagnostic for multiple ovarian Leydig cell tumors.

Conclusion: The most frequent cause of postmenopausal hyperandrogenism is polycystic ovary syndrome. It is necessary to exclude the presence of neoplastic causes (ovarian or adrenal androgen- secreting tumors). In case of marked virilization and severe hyperandrogenism, it is useful to perform transvaginal ultrasonography to search for the presence of ovarian hypertrichosis or androgen-secreting ovarian tumors and a CT/RM scan to study the adrenal glands. The best treatment for hyperandrogenism of neoplastic origin is surgery. Patients who are not candidates for this approach are candidates for therapy with GnRH agonists.

Cite this article as:

Visconti Felicia*, Garino Francesca, Corneli Ginevra, Libera Balbo Marcella, Gottero Cristina, Sansone Daniela and Endrio Oleandri Salvatore, Case Report: Hyperandrogenism in Menopause, Endocrine, Metabolic & Immune Disorders - Drug Targets 2024; 24 () . https://dx.doi.org/10.2174/0118715303322604240722102207